Press Releases

The following UK & Ireland Press Releases contain information that is intended for journalists only.
For media enquiries about our press releases please contact mediaenquiries.UK-IE@ipsen.com.

CRSC-GB-000067

June 2023


8 results

Ipsen Wrexham investment unveiled as Wrexham mayor joins 50t...

WREXHAM, UK, 13 June 2023 – Ipsen today announced a £75 million investment in its…

Ipsen’s response to NICE’s decision on Cabometyx® (cabozanti...

SLOUGH, UK, 5th April 2023 – Ipsen is disappointed that the National Institute for Health…

NICE recommends Cabometyx® (cabozantinib) for previously tre...

Cabozantanib has been recommended by NICE as an option for treating advanced hepatocellular carcinoma (HCC),…

Tánaiste joins Ipsen Ireland to launch upgraded manufacturin...

Dublin, Ireland, 25th/26th September 2022 Tánaiste joins Ipsen Ireland to launch upgraded manufacturing site in…

Ipsen announced overall Pharma Industry Company of the Year ...

Ireland, May 2022 Blanchardstown-based, biopharmaceutical Ipsen has been announced overall Pharma Industry Company of the…

Ipsen appoints Guy Oliver as General Manager, UK & Irela...

SLOUGH, UK, 21 March 2022 — Ipsen (Euronext: IPN; ADR: IPSEY) today announced the appointment…

Secretary of State for Wales marks new investment in Ipsen’s...

WREXHAM, UK, 24 February 2022 Today, Simon Hart MP, Secretary of State for Wales, visited…

Advanced kidney cancer patients in Scotland become amongst t...

Advanced kidney cancer patients in Scotland become amongst the first in world to access CABOMETYX®▼…

© Ipsen Group 2024